Transaction Advisory

Mergers and Acquisitions Sell-side

Experience and stability you can count on

When you choose Alira Health, you’ll benefit from more than two decades of in-depth expertise. Our M&A Sell-side team specializes in serving:

  • A range of companies with €5-250M valuation
  • Cross-border small- and mid-cap deals

Alira Health is a FINRA (USA) and ORIAS (EU) certified firm.

Why choose Alira Health?

As our partner, you’ll also have access to Alira Health’s in-house clinical, regulatory, and market access experts to capture the full value of your assets.

Our recent projects included an advisory role in:

  • A DNA testing company in its sale
  • A specialized contract manufacturer of precision plastic components and devices in its acquisition

Related news

Events October 6, 2022
The MedTech Conference 2022
We are pleased to share that we will be joining the MedTech Conference 2022 as sponsors and speakers! This year’s edition will have more than 100 sessions focusing on today’s hot topics.
M&A MedTech Regulatory
News January 13, 2022
Alira Health Secures an Additional $40M in Funding, Led by Creadev
We announced today the closing of an equity financing in which it raised gross proceeds of US$40 million. We intend to use the funds to invest in solutions that actively engage patients(...)
M&A MedTech Pharma
Publications August 3, 2021
What You Should Know Before Choosing a Healthcare Transaction Advisory Firm
What’s most important when selecting a firm for your next transaction? Global experience, staff profiles, technical expertise? To learn more read our latest TAD Infographic.
M&A
News April 12, 2021
Alira Health Strengthens its Growth Strategy with a $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.
M&A MedTech Pharma
News December 20, 2020
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
M&A Pharma
News November 29, 2020
We Announce our Role as Strategic Advisor to Benvic in the Acquisition of Luc & Bel
We are proud to announce our role as strategic advisor to Benvic in the acquisition of Luc & Bel.
M&A
Publications November 1, 2020
Five Key Success Factors for Managing Transactions in Full Virtual Mode
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
M&A
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.